← Eichor
Condition: Hepatic Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hepatic Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
Phase 1 · 1 location(s) · Lee's Pharmaceutical Limited · NCT06374485Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Phase N/A · 1 location(s) · Tongji Hospital · NCT05520788Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
Phase N/A · 3 location(s) · University of California, San Diego · NCT05705219A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224750Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Phase 2 · 2 location(s) · Chen Xiaoping · NCT06420440A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be
Phase 2 · 3 location(s) · Asan Medical Center · NCT07010497bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
NA · 1 location(s) · Sun Yat-sen University · NCT06061276Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Phase 1/Phase 2 · 2 location(s) · Zhejiang Cancer Hospital · NCT06741020A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NA · 2 location(s) · Nantes University Hospital · NCT06735560EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Phase 1/Phase 2 · 29 location(s) · Grey Wolf Therapeutics · NCT06923761First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT07679061Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen
Phase 1/Phase 2 · 49 location(s) · Pfizer · NCT07227012To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
NA · 1 location(s) · Chinese PLA General Hospital · NCT04365751Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Phase 2 · 4 location(s) · Seoul National University Hospital · NCT06773845Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07272200A Multicenter Cancer Biospecimen Collection Study
Phase N/A · 1 location(s) · Cofactor Genomics, Inc. · NCT04510129PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
Phase 1 · 2 location(s) · West China Hospital · NCT07053072A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage Hepato
Phase 3 · 72 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT04803994Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274Evaluating Novel Therapies in ctDNA Positive GI Cancers
Phase 3 · 3 location(s) · Georgetown University · NCT05482516Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06607107Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhos
Phase 2 · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT06526104At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta
Phase 1/Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT06811116Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
Phase 2 · 1 location(s) · West China Hospital · NCT06664996
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.